Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT02320669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 220 participants
- Sponsor
- Seattle Children's Hospital
- Registry
-
NCT02320669
-
- Other papers using this trial's data
- Triiodothyronine Supplementation in Infants Undergoing Cardiopulmonary Bypass: A Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02320669. Randomized; triple masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2019-10 (actual). Results posted on 2024-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
- Acronym
- TRICC-2
- Condition
- Congenital Heart Defects
- Intervention (Drug)
- Triostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Seattle Children's Hospital
Record details
- Record id
cardio:ct-nct02320669- Content hash
a8d61e98479e90b4f9485f51fb6bbea4e371d4700a87b6d608daa65983bf321f